Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

GlobeNewswire Inc.

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

GlobeNewswire Inc.

Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference

GlobeNewswire Inc.

Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?

Zacks Investment Research

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

GlobeNewswire Inc.

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research

Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know

Zacks Investment Research

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?

Zacks Investment Research

Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?

Zacks Investment Research

Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development

Zacks Investment Research

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why

Zacks Investment Research

How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%

Zacks Investment Research